Core Viewpoint - Kamada Ltd. is actively participating in key healthcare investment conferences to enhance investor engagement and showcase its growth strategy in the biopharmaceutical sector [1][2]. Company Overview - Kamada Ltd. is a global biopharmaceutical company specializing in rare and serious conditions, particularly in the specialty plasma-derived therapies field [3]. - The company has a portfolio of six FDA-approved specialty plasma-derived products, including KEDRAB, CYTOGAM, GLASSIA, WINRHO SDF, VARIZIG, and HEPAGAM B, along with other proprietary products [3]. Growth Strategy - The company's growth strategy is built on four primary pillars: 1. **Organic Growth**: Focus on commercialization and life cycle management of proprietary products, including the launch of several biosimilar products in Israel [3]. 2. **Business Development**: Pursue new business opportunities through in-licensing, collaborations, and mergers and acquisitions to enhance its product portfolio [3]. 3. **Plasma Collection Expansion**: Increase plasma collection operations to support revenue growth and meet the demand for hyper-immune plasma, with three operating centers in Texas [3]. 4. **R&D Advancements**: Leverage manufacturing and research expertise to develop additional product candidates, with a focus on the InnovAATe clinical trial for Inhaled AAT [3]. Conference Participation - CEO Amir London will present at the 2025 Wells Fargo Healthcare Conference on September 3, 2025, and at the H.C. Wainwright 27 Annual Global Investment Conference on September 8, 2025, with opportunities for one-on-one investor meetings [2][3].

Financial Data and Key Metrics Changes - Total revenues for the first half of 2025 were $88.8 million, representing an 11% year-over-year increase, while adjusted EBITDA was $22.5 million, up 35% year-over-year, with a 25% margin on revenues [4][11] - For the second quarter, revenues were $44.8 million, up 5% compared to the prior year quarter, and adjusted EBITDA was $10.9 million, up 20% year-over-year [4][11] - Net income for the first half of 2025 was $11.3 million or $0.19 per diluted share, compared to $6.8 million or $0.12 per diluted share in 2024 [13][14] Business Line Data and Key Metrics Changes - Revenue growth for the first half of 2025 was primarily driven by increased sales of Glacier in ex-U.S. markets and VariSig sales in the U.S., as well as Glacier royalty payments [6][7] - The company anticipates launching two additional biosimilars later this year, with expected revenues of approximately $2.5 million in 2025 from the first biosimilar launched in Israel [7][8] Market Data and Key Metrics Changes - The company is ramping up plasma collection at its Texas-based plasma centers, with each center expected to generate annual revenues of between $8 million to $10 million at full capacity [9] - The market for inhaled alpha-one antitrypsin therapy is projected to grow significantly, with expectations that it could reach a $2 billion market by the time the company has results from its study [26] Company Strategy and Development Direction - The company is guided by a four-pillar growth strategy focusing on organic commercial growth, business development and M&A transactions, plasma collection operations, and the advancement of its pivotal Phase III Inhaled AAT program [5][41] - The company is actively conducting due diligence on several potential commercial targets to enrich its portfolio and expects to secure compelling in-licensing collaborations or M&A transactions [8][23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in continuing to generate profitable growth through the remainder of 2025 and has increased its adjusted EBITDA guidance to between $40 million to $44 million [5][14] - The company is closely monitoring the evolving tariff situation, assessing that recently imposed tariffs are not applicable to drug products and have not impacted operations [15] Other Important Information - The company ended the first half of 2025 with a cash balance of $66 million, which is planned to be used for new business development initiatives [14] - Gross profit for the first half of 2025 was $39.7 million with a gross margin of 45%, compared to $35.7 million and 45% in 2024 [12] Q&A Session Summary Question: Dynamics behind KEDRAB and Cytogam - Management indicated that KEDRAB and Cytogam are performing according to expectations, with growth anticipated once additional clinical data is available [17][19] Question: Cash position for impactful business development - Management plans to utilize existing cash and has additional funding sources available for commercial stage assets, focusing on plasma-derived products and specialty pharma [22][23] Question: Competitive landscape for inhaled AAT program - Management noted that their inhaled AAT program is the most advanced in terms of efficacy studies, with a growing market and multiple new technologies being developed [24][26] Question: Distribution revenue segment and future outlook - Management confirmed that the revenue from the new biosimilar product is not a one-time sale and expects continued growth in the distribution channel [30][31] Question: SG&A expenses and future expectations - Management stated that they have been disciplined in managing expenses and anticipate a slight fluctuation in the second half of the year but aim to maintain profitability [33][34] Question: Tax rate expectations - Management expects an effective tax rate between 20% and 25% as the company utilizes its tax loss carryforwards [35][38]

Company Overview - Kamada Ltd. is a global biopharmaceutical company focused on rare and serious conditions, specializing in specialty plasma-derived therapies [3] - The company has a portfolio of six FDA-approved specialty plasma-derived products, including KEDRAB®, CYTOGAM®, GLASSIA®, WINRHO SDF®, VARIZIG®, and HEPAGAM B® [3] - FIMI Opportunity Funds is the controlling shareholder, owning approximately 38% of the outstanding ordinary shares [3] Financial Results Announcement - Kamada will release its financial results for the second quarter and first half ended June 30, 2025, prior to the U.S. market opening on August 13, 2025 [1] - An investment community conference call will be held on August 13 at 8:30am ET to discuss the results and answer questions [2] Growth Strategy - The company aims for organic growth through commercialization and life cycle management of its proprietary products [3] - Kamada is pursuing new business development opportunities, including in-licensing, collaboration, and mergers and acquisitions to enhance its product portfolio [3] - The company is expanding plasma collection operations to support revenue growth and increasing demand for hyper-immune plasma [3] - Kamada is advancing the development of additional product candidates, with a focus on unmet medical needs, including the InnovAATe clinical trial for Inhaled AAT [3]

Core Viewpoint - Kamada Ltd. continues its operations and manufacturing in Israel despite evolving circumstances in the Middle East, ensuring that the global availability of its products remains uninterrupted [1][2]. Company Overview - Kamada Ltd. is a global biopharmaceutical company specializing in products for rare and serious conditions, particularly in the specialty plasma-derived therapies field [3]. - The company has a portfolio of six FDA-approved specialty plasma-derived products, including KEDRAB®, CYTOGAM®, GLASSIA®, WINRHO SDF®, VARIZIG®, and HEPAGAM B®, along with other proprietary products and biosimilars [3]. - FIMI Opportunity Funds is the controlling shareholder, owning approximately 38% of the outstanding ordinary shares [3]. Business Continuity and Operations - The company is focused on business continuity and has sufficient product levels available through distribution centers outside Israel, despite temporary disruptions due to the closing of Israeli airspace [2][4]. - Kamada is actively monitoring the situation and prioritizing the well-being of its employees while ensuring that client demands are met without shortages [2][4]. Growth Strategy - Kamada's growth strategy is built on four pillars: organic growth through commercialization, securing new business development opportunities, expanding plasma collection operations, and advancing product candidates in development [3]. - The company operates three plasma collection centers in the United States to support revenue growth and meet increasing demand for hyper-immune plasma [3]. - The lead product candidate is Inhaled AAT, currently progressing through the InnovAATe clinical trial, a pivotal Phase 3 trial [3].

Company Overview - Kamada Ltd. is a global biopharmaceutical company focused on rare and serious conditions, specializing in specialty plasma-derived therapies [3] - The company has a portfolio of six FDA-approved specialty plasma-derived products, including KEDRAB®, CYTOGAM®, GLASSIA®, WINRHO SDF®, VARIZIG®, and HEPAGAM B® [3] - FIMI Opportunity Funds is the controlling shareholder, owning approximately 38% of the outstanding ordinary shares [3] Financial Results Announcement - Kamada will release its financial results for the first quarter ending March 31, 2025, prior to the opening of U.S. financial markets on May 14, 2025 [1] - An investment community conference call will be held on the same day at 8:30am ET to discuss the results and answer questions [2] Growth Strategy - The company aims for organic growth through commercialization and life cycle management of its proprietary products [3] - Kamada is pursuing new business development opportunities, including in-licensing, collaboration, and M&A to enhance its product portfolio [3] - The company is expanding plasma collection operations to support revenue growth and meet increasing demand for hyper-immune plasma [3] - Kamada is advancing the development of additional product candidates, with a focus on unmet medical needs, including the InnovAATe clinical trial for Inhaled AAT [3]